Revenue
2021
2022
2023
2024
2025
Krystal Biotech, Inc. (KRYS)
Price$358.24Cached quote
Net income
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $389.1M | $290.5M | $50.7M | $0 | $0 | — | — | — | — | — |
| Research & development | $58.0M | $53.6M | $46.4M | $42.5M | $27.9M | $17.9M | $15.6M | $7.8M | $3.2M | $741,000 |
| Operating expenses | $227.8M | $224.8M | $160.3M | $145.2M | $68.3M | $33.0M | $22.1M | $11.9M | $4.8M | $1.1M |
| Operating income | $161.3M | $65.7M | −$109.6M | −$145.2M | −$68.3M | −$33.0M | −$22.1M | −$11.9M | −$4.8M | −$1.1M |
| Operating margin | 41.45% | 22.63% | −216.21% | — | — | — | — | — | — | — |
| EBITDA | $167.0M | $71.7M | −$104.6M | −$141.1M | −$65.5M | −$31.1M | −$21.0M | −$11.8M | −$4.7M | −$1.1M |
| EBITDA margin | 42.92% | 24.69% | −206.34% | — | — | — | — | — | — | — |
| Net income | $204.8M | $89.2M | $10.9M | −$140.0M | −$69.6M | −$32.2M | −$19.1M | −$10.9M | −$7.9M | −$1.1M |
| Net profit margin | 52.64% | 30.69% | 21.56% | — | — | — | — | — | — | — |
| Basic EPSper basic share | $7.08 | $3.12 | $0.40 | -$5.49 | -$3.13 | -$1.71 | -$1.20 | -$0.97 | -$1.48 | -$1.31 |
| Diluted EPSper diluted share | $6.84 | $3.00 | $0.39 | -$5.49 | -$3.13 | -$1.71 | -$1.20 | -$0.97 | -$1.48 | -$1.31 |
Owners
Reported shareholders
14.93%of listed shares
FMR LLC4.42M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
FMR LLC | 14.93%4.42M shares |
BlackRock, Inc. | 14.13%4.18M shares |
Avoro Capital Advisors LLC | 9.76%2.89M shares |
Krishnan Krish S | ≈5.37%1.59M shares |
VANGUARD PORTFOLIO MANAGEMENT LLC | 5.32%1.57M shares |
Krishnan Suma | ≈5.13%1.52M shares |
STATE STREET CORP | 4.57%1.35M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 4.19%1.24M shares |
Soleus Capital Management, L.P. | 3.17%939.25K shares |
Capital World Investors | 2.63%777.84K shares |
VESTOR CAPITAL, LLC | 2.37%700.91K shares |
GEODE CAPITAL MANAGEMENT, LLC | 2.36%698.99K shares |
PRICE T ROWE ASSOCIATES INC /MD/ | 2.32%687.4K shares |
Hood River Capital Management LLC | 2.24%663.38K shares |
Redmile Group, LLC | 2.14%632.01K shares |
WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | 1.93%570.15K shares |
Frazier Life Sciences Management, L.P. | 1.63%481.31K shares |
DIMENSIONAL FUND ADVISORS LP | 1.61%476.04K shares |
FIRST TRUST ADVISORS LP | 1.10%324.9K shares |
Invesco Ltd. | 1.10%324.76K shares |
Percentages use 29.6M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 25, 2026Form 4 · 10b5-1 | Thomas John CharlesEVP, General Counsel | SellCommon Stock | 1.0K | $347.27 | $347.3K | 0 |
| Jun 4, 2026Form 4 · 10b5-1 | Krishnan SumaPresident, R&D | SellCommon Stock | 240 | $311.65 | $74.8K | 1.38M |
| Jun 4, 2026Form 4 · 10b5-1 | Krishnan SumaPresident, R&D | SellCommon Stock | 2.0K | $310.94 | $634.0K | 1.38M |
| Jun 4, 2026Form 4 · 10b5-1 | Krishnan SumaPresident, R&D | SellCommon Stock | 2.8K | $309.95 | $868.2K | 1.38M |
| Jun 4, 2026Form 4 · 10b5-1 | Krishnan SumaPresident, R&D | SellCommon Stock | 3.8K | $308.89 | $1.17M | 1.38M |